AstraZeneca receives EU recommendation for Enhertu and US FDA priority review

AstraZeneca has received a recommendation from the European Medicines Agency (EMA) for the use of Enhertu in treating HER2-positive breast cancer in adults following surgery. This recommendation follows Phase III clinical data demonstrating measurable effects compared to current standards of care.

Simultaneously, the company is undergoing a prioritized FDA review in the United States for Efzimfotase alfa. These developments represent significant regulatory milestones for AstraZeneca, spanning two distinct therapeutic areas: oncology via antibody-drug conjugates in Europe and rare diseases in the United States.